Definium Therapeutics Inc. Common Shares (DFTX)

About DFTX

Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company's lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the…

Sector

Health Care

Industry

Medicinal Chemicals and Botanical Products

Employees

105

Website

definiumtx.com/

Fundamentals

1-day range

$40.85$43.38

Market cap

$4.56B

P/E (trailing)

—

P/E (forward)

-21.85

EPS (trailing)

$-3.43

Dividend yield

—

Beta

2.23

Avg. volume

2.97M

Forecasts

17 analyst ratings

Definium Therapeutics Inc. Common Shares Competitors

Chosen by industry and closest market cap.

• DFTX

  Definium Therapeutics Inc. Common Shares

  $41

  ▼ 6.44%
  Market cap $4.56BP/E —
  $8.7$49.7
• RLX

  RLX Technology Inc. American Depositary Shares each representing the right to receive one (1) Class A ordinary share

  $1.83

  ▲ 1.67%
  Market cap $3.08BP/E 16.68
  $1.76$2.84
• RGC

  Regencell Bioscience Holdings Limited Ordinary Shares

  $5.52

  ▼ 0.09%
  Market cap $3.03BP/E —
  $4.51$69
• TRLV

  Trulieve Cannabis Corp. Subordinate Voting Shares

  $11.82

  ▲ 7.16%
  Market cap $1.65BP/E —
  $7.82$12.3
• GLAS

  Glass House Brands Inc. Subordinate Voting Shares

  $9.92

  ▲ 1.43%
  Market cap $790.50MP/E —
  $5.03$14
• TLRY

  Tilray Brands Inc. Common Stock

  $4.58

  ▲ 0.22%
  Market cap $540.66MP/E —
  $3.67$23.2
• CGC

  Canopy Growth Corporation Common Shares

  $1.01

  ▲ 0.00%
  Market cap $411.45MP/E —
  $1.18$3.28

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• B of A Securities Initiates Coverage On Definium Therapeutics with Buy Rating, Announces Price Target of $75
  benzinga · 8/18/2026
• This Definium Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
  Benzinga · 8/18/2026
• B of A Securities Initiates Coverage On Definium Therapeutics with Buy Rating, Announces Price Target of $75
  Benzinga · 8/18/2026
• Maxim Group Maintains Buy on Definium Therapeutics, Raises Price Target to $55
  Benzinga · 8/14/2026
• Jones Trading Maintains Buy on Definium Therapeutics, Raises Price Target to $90
  Benzinga · 8/13/2026
• Canaccord Genuity Maintains Buy on Definium Therapeutics, Raises Price Target to $64
  Benzinga · 8/13/2026
• RBC Capital Maintains Outperform on Definium Therapeutics, Raises Price Target to $66
  Benzinga · 8/13/2026
• Wells Fargo Maintains Overweight on Definium Therapeutics, Raises Price Target to $72
  Benzinga · 8/13/2026
• Baird Maintains Outperform on Definium Therapeutics, Raises Price Target to $75
  Benzinga · 8/13/2026

• Robert Barrow · August 12, 2026 · Grant

  375.0K
• Karlin Daniel · August 12, 2026 · Grant

  100.0K
• Matthew T. Wiley · August 12, 2026 · Grant

  62.5K
• Brandi Roberts · August 12, 2026 · Grant

  62.5K
• Mark Sullivan · August 12, 2026 · Grant

  62.5K
• Karlin Daniel · June 25, 2026 · Sale

  10.0K @ $45.03
• Robert Barrow · June 25, 2026 · Sale

  29.2K @ $45.03
• Matthew T. Wiley · June 25, 2026 · Sale

  2.9K @ $45.03
• Brandi Roberts · June 25, 2026 · Sale

  3.0K @ $45.03
• Mark Sullivan · June 25, 2026 · Sale

  13.0K @ $45.03
• Robert Barrow · June 22, 2026 · Grant

  375.0K
• Karlin Daniel · June 22, 2026 · Grant

  100.0K
• Matthew T. Wiley · June 22, 2026 · Grant

  62.5K
• Brandi Roberts · June 22, 2026 · Grant

  62.5K
• Mark Sullivan · June 22, 2026 · Grant

  62.5K

Institutional Ownership

March 31, 2026

Total shares held

78.08M

Total value held

$1.47B

Institutional holders

242